Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Apply for the Fierce AI Innovation Awards - Submissions close Thursday, June 18
combination therapy
Pharma
Lilly oncology chief ‘blown away’ by new Jaypirca CLL data
The addition of Jaypirca to a fixed-duration regimen with venetoclax and rituximab improved PFS by 45.3% in previously treated CLL.
Angus Liu
Jun 15, 2026 8:25am
ASCO: Incyte positions Monjuvi combo for first-line DLBCL
May 30, 2026 8:00am
Merck's Welireg surprisingly fails in first-line kidney cancer
Apr 21, 2026 10:00am
Another AstraZeneca Emerald glimmers in liver cancer
Apr 2, 2026 10:12am
Pfizer eyes earlier Talzenna use after ph. 3 prostate cancer win
Mar 19, 2026 6:45am
Merck's Welireg combos deliver 1-2 punch to kidney cancer
Feb 28, 2026 10:00am
